New fast-RSOM Imaging Technology Developed for Early Cardiovascular Risk Detection

Introduction to fast-RSOMResearchers from Helmholtz Munich and the Technical University of Munich (TUM) have developed "fast-RSOM," an imaging technology. This technology is capable of capturing detailed images of small blood vessels directly through the skin without invasive procedures. The aim is to reveal early signs of cardiovascular risk, enabling earlier medical intervention, guiding personalized therapies, and improving long-term heart health.## Microvascular Health AssessmentMicrovascular endothelial dysfunction (MiVED), which involves changes in the ability of small blood vessels to expand and contract, is an early indicator of cardiovascular disease. Previously, doctors lacked a precise and non-invasive method to observe these early changes in humans. Dr. Hailong He, a study author from Helmholtz Munich and TUM, stated that fast-RSOM allows non-invasive assessment of endothelial dysfunction at single-capillary and skin-layer resolution in humans. Dr. Angelos Karlas, a co-author and Vascular Surgeon at TUM University Hospital, noted the approach provides a view of how cardiovascular disease manifests at the microvascular level.## Early Detection of Disease ProgressionFast-RSOM provides high-resolution, dynamic MiVED biomarkers that describe impairments in blood vessel function. These impairments are generally present before clinical symptoms or measurable macroscopic disease features appear. Such early changes are often linked to risk factors like smoking, high blood pressure, or obesity. Fast-RSOM can quantitatively capture the changes these conditions impose on the microvascular system before major complications develop, contrasting with risk calculation based solely on descriptive conditions. This capability supports new possibilities for early detection, prevention, and precise monitoring of cardiovascular health. The technology could identify individuals at higher risk of cardiovascular events and monitor the impact of lifestyle or therapeutic interventions.## Path to Clinical ApplicationThe research team plans to validate fast-RSOM in larger patient groups and integrate its biomarkers into clinical workflows. Due to its portability, speed, and non-invasive nature, the device may be used in outpatient clinics for routine cardiovascular risk assessment. Prof. Vasilis Ntziachristos, Director of the Bioengineering Center at Helmholtz Munich and Professor at TUM, indicated that fast-RSOM could change how cardiovascular diseases are prevented and managed, potentially improving patient outcomes and reducing healthcare costs.## What is RSOM?RSOM (Raster Scan Optoacoustic Mesoscopy) is a non-invasive imaging technology that uses light pulses to generate ultrasound signals. This process creates detailed 3D images of structures beneath the skin. It can detect changes in blood vessels, oxygen levels, and tissue composition not visible with traditional imaging. RSOM combines high contrast with depth, supporting early detection of diseases such as cardiovascular problems and diabetes. Its compact design may facilitate advanced diagnostics outside specialized laboratories.